DexCom (NASDAQ:DXCM) Price Target Raised to $160.00 at Raymond James

DexCom (NASDAQ:DXCM) had its price target boosted by Raymond James from $151.00 to $160.00 in a research note published on Friday, Benzinga reports. They currently have a strong-buy rating on the medical device company’s stock.

Several other research firms have also commented on DXCM. Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an outperform rating and a $165.00 price objective for the company. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the stock a buy rating in a report on Friday. UBS Group lifted their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a buy rating in a research note on Wednesday, April 10th. StockNews.com downgraded DexCom from a buy rating to a hold rating in a research report on Tuesday. Finally, Citigroup lifted their price target on DexCom from $148.00 to $161.00 and gave the stock a buy rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of Moderate Buy and an average price target of $141.67.

DexCom Stock Performance

DexCom stock opened at $124.34 on Friday. DexCom has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a market capitalization of $49.24 billion, a PE ratio of 80.22, a P/E/G ratio of 2.37 and a beta of 1.20. The company has a 50 day moving average price of $131.13 and a 200-day moving average price of $118.30. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.38% and a net margin of 16.82%. The business had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. As a group, equities analysts forecast that DexCom will post 1.76 earnings per share for the current year.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the sale, the chief operating officer now owns 273,913 shares of the company’s stock, valued at $36,816,646.33. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, COO Jacob Steven Leach sold 14,639 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the sale, the chief operating officer now owns 273,913 shares in the company, valued at approximately $36,816,646.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock worth $25,530,859 in the last 90 days. Insiders own 0.41% of the company’s stock.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DSM Capital Partners LLC acquired a new stake in shares of DexCom in the fourth quarter valued at $28,000. Valley National Advisers Inc. raised its position in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co purchased a new position in shares of DexCom in the 1st quarter valued at about $32,000. MV Capital Management Inc. grew its position in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares in the last quarter. Finally, Smithfield Trust Co increased its stake in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.